Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis
Introduction. Treatment with a glucagon-like peptide 1 (GLP-1) analog fails in some patients due to rebound hyperglycemia caused by tachyphylaxis (GLP-1 tachyphylaxis). We investigated the efficacy of basal-supported oral therapy (BOT) with insulin glargine and sitagliptin for counteracting GLP-1 ta...
Saved in:
Main Authors: | Shu Meguro, Toshihide Kawai, Tomohiro Matsuhashi, Motoaki Sano, Keiichi Fukuda, Hiroshi Itoh, Yoshihiko Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2014/927317 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chorea Hyperglycemia Basal Ganglia Syndrome in a 63-Year-Old Male
by: Michael Sperling, et al.
Published: (2018-01-01) -
The Improvement of Hyperglycemia after RYGB Surgery in Diabetic Rats Is Related to Elevated Hypothalamus GLP-1 Receptor Expression
by: Jazyra Zynat, et al.
Published: (2016-01-01) -
Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals
by: Yingxiao Li, et al.
Published: (2025-01-01) -
Deciphering the Topology of Sitagliptin Using an Integrated Approach
by: Renny Mathew, et al.
Published: (2025-01-01) -
Synchronization and Rebound Effects in Residential Loads
by: Nora Agah, et al.
Published: (2024-01-01)